A single line often inverts meaning once you see what it
answers, so neighbouring messages are always shown.
-
Good afternoon Emily, OMA/DPI received questions related to an FBI inquiry for the following NIAID grants: 1R01AI110964-01 through 2R01AI110964-06. The agent is requesting clarification on the details of the study, where certain aspects were performed, and whether seamless cloning techniques were used. I note you were the last official to sign off on 4/27/20. Would you be able to provide a response to the below-captured questions and/or be available for a joint call with our office and the agent? If not, who would be the best SME on this matter? I'm sure you understand, since this is a sensitive matter, we need to maintain confidentiality and limit the touch-points within NIH. I'm happy to discuss further if you have any questions. yt tes ing rt (Db >E2 Expressing Mice with dn experiments as described this occurred? Thank you, Ashley Ashley M. Sanders, MPS Senior Program Investigations Officer NIH, OMA, Division Program Integrity 6011 Executive Blvd. Rockville, Maryland 20852 Office: @nih.gov FBI Questions: SF 424 AI110964-06 (received date 11/05/2018) Both SF 424s seem to be describing "gain of function" experiments. On page 192 of SF 424 AI110964-06 (received date 11/05/2018) under P3CO Research, it indicates they are conducting gain of function of SARSr-CoV. Were they also conducting Seemless Cloining and Assembly? From a review of their experimental details, it looks as if they were generating recombinant DNA of the viruses using WIV1 as the backbone but I could not determine if they were using Seemless Cloning techniques. I could not determine exactly where they were conducting these gain of function experiments. I know UNC-Chapel Hill has done these but within the document, I could not determine where this was occurring. Do you know where this was occurring? It then appears that the recombinant DNA of the virus was then injected into humanized mice. However, again I couldn't determine where this occurred or was to occur. On page 187 of the same SF 424 under "Vertebrate Animals" it indicates that work with vertebrate animals will be conducted at Wuhan University at the School of Medicine and UNC - CH. Then under "Laboratory Mice" it states that lab mice will be sourced commercially by Wuhan Center for Animal Experiment at Wuhan University and that humanized mice will be bread at University of Wuhan and UNC - CH. Furthermore, the mice will be inoculated with the virus. Under "UNC Facilities where selected agents to be used" it continues with all mouse studies at UNC-CH will be performed...." However, on page 200 of the same SF 424 there is a letter from UNC - CH stating "The work to be performed by UNC-CH does not include animal and/or human research subjects." I know that was a lot of information but where exactly was the experimentation of injecting the humanized mice with the recombinant DNA occurring? SF 424 AI110964-01 (received date 06/05/2013) In this SF 424 Aim 3 seems indicative of gain of function experimentation (C3a and C3b) although it does not use that exact term. On page 119 of AI110964-01 under "C3d) Humanized mouse in vivo infection experiments" it states that humanized mouse in vivo experiments in humanized mice was occurring at the Wuhan Institute of Virology. I did not see the location where these gain of function experiments were being done but if the injections were occurring at WIV then was the recombinant DNA also generated at WIV? Was Seemless Cloning also being done? RPPR (AI110964-05) Finally, in the RPPR (6/1/2017-5/31/2018) on page 28 under "In Vivo Infection of Human ACE2 Expressing Mice with SARSr-Cov S Protein variants", it appears to be showing the results from their gain of function experiments as described in the SF 424. This is more of less the same as the question above, but do you know where this occurred? wh.iov.cn> 20 6:30 AM EDT
-
Good afternoon Emily, OMA/DPI received questions related to an FBI inquiry for the following NIAID grants: 1R01AI110964-01 through 2R01AI110964-06. The agent is requesting clarification on the details of the study, where certain aspects were performed, and whether seamless cloning techniques were used. I note you were the last official to sign off on 4/27/20. Would you be able to provide a response to the below-captured questions and/or be available for a joint call with our office and the agent? If not, who would be the best SME on this matter? I'm sure you understand, since this is a sensitive matter, we need to maintain confidentiality and limit the touch-points within NIH. I'm happy to discuss further if you have any questions. Thank you, Ashley Ashley M. Sanders, MPS Senior Program Investigations Officer NIH, OMA, Division Program Integrity 6011 Executive Blvd. Rockville, Maryland 20852 Office: @nih.gov FBI Questions: vt tes en at ing ot (Db >E2 Expressing Mice with on experiments as described this occurred? SF 424 AI110964-06 (received date 11/05/2018) Both SF 424s seem to be describing "gain of function" experiments. On page 192 of SF 424 AI110964-06 (received date 11/05/2018) under P3CO Research, it indicates they are conducting gain of function of SARSr-CoV. Were they also conducting Seemless Cloining and Assembly? From a review of their experimental details, it looks as if they were generating recombinant DNA of the viruses using WIV1 as the backbone but I could not determine if they were using Seemless Cloning techniques. I could not determine exactly where they were conducting these gain of function experiments. I know UNC-Chapel Hill has done these but within the document, I could not determine where this was occurring. Do you know where this was occurring? It then appears that the recombinant DNA of the virus was then injected into humanized mice. However, again I couldn't determine where this occurred or was to occur. On page 187 of the same SF 424 under "Vertebrate Animals" it indicates that work with vertebrate animals will be conducted at Wuhan University at the School of Medicine and UNC - CH. Then under "Laboratory Mice" it states that lab mice will be sourced commercially by Wuhan Center for Animal Experiment at Wuhan University and that humanized mice will be bread at University of Wuhan and UNC - CH. Furthermore, the mice will be inoculated with the virus. Under "UNC Facilities where selected agents to be used" it continues with all mouse studies at UNC-CH will be performed...." However, on page 200 of the same SF 424 there is a letter from UNC - CH stating "The work to be performed by UNC-CH does not include animal and/or human research subjects." I know that was a lot of information but where exactly was the experimentation of injecting the humanized mice with the recombinant DNA occurring? SF 424 AI110964-01 (received date 06/05/2013) In this SF 424 Aim 3 seems indicative of gain of function experimentation (C3a and C3b) although it does not use that exact term. On page 119 of AI110964-01 under "C3d) Humanized mouse in vivo infection experiments" it states that humanized mouse in vivo experiments in humanized mice was occurring at the Wuhan Institute of Virology. I did not see the location where these gain of function experiments were being done but if the injections were occurring at WIV then was the recombinant DNA also generated at WIV? Was Seemless Cloning also being done? RPPR (AI110964-05) Finally, in the RPPR (6/1/2017-5/31/2018) on page 28 under "In Vivo Infection of Human ACE2 Expressing Mice with SARSr-Cov S Protein variants", it appears to be showing the results from their gain of function experiments as described in the SF 424. This is more of less the same as the question above, but do you know where this occurred? From: "Stemmy, Erik (NIH/NIAID) [E]" </O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=585133D3FA194F06AA618678B2817C22STEMMYEJ> To: "Linde, Emily (NIH/NIAID) [E]" < @mail.nih.gov>, "Sanders, Ashley (NIH/OD) [E]" < @nih.gov> Cc: "Shannon, Mike (NIH/OD) [E]" < @nih.gov> Subject: RE: Grant Questions - FBI Inquiry - 1-R01AI110964-01 - 2-R01AI110964-06 Date: Thu, 21 May 2020 11:22:11 -0400 Importance: Normal Hi Ashley, I would be happy to answer questions related to this award. Would it be best if I just addressed the comments at the end of this email thread? I'll say generally that NIAID has an extensive review process for P3CO (and formerly for GoF) and that all of this work was formally evaluated by the respective committees and determined not to be gain-of-function, nor subject to P3CO oversight. We also continually monitored the progress (until the award was terminated) for evidence of unexpected increases in viral replication. Erik Erik J. Stemmy, Ph.D. Program Officer Respiratory Diseases Branch Division of Microbiology and Infectious Diseases NIAID/NIH/HHS 5601 Fishers Lane, Room 8E18 Bethesda, MD 20892-9825 Phone: Email: @nih.gov
-
Good afternoon Emily, OMA/DPI received questions related to an FBI inquiry for the following NIAID grants: 1R01AI110964-01 through 2R01AI110964-06. The agent is requesting clarification on the details of the study, where certain aspects were performed, and whether seamless cloning techniques were used. I note you were the last official to sign off on 4/27/20. Would you be able to provide a response to the below-captured questions and/or be available for a joint call with our office and the agent? If not, who would be the best SME on this matter? I'm sure you understand, since this is a sensitive matter, we need to maintain confidentiality and limit the touch-points within NIH. I'm happy to discuss further if you have any questions. Thank you, Ashley Ashley M. Sanders, MPS Senior Program Investigations Officer NIH, OMA, Division Program Integrity 6011 Executive Blvd. Rockville, Maryland 20852 Office: @nih.gov FBI Questions: SF 424 AI110964-06 (received date 11/05/2018) Both SF 424s seem to be describing "gain of function" experiments. On page 192 of SF 424 AI110964-06 (received date 11/05/2018) under P3CO Research, it indicates they are conducting gain of function of SARSr-CoV. Were they also conducting Seemless Cloining and Assembly? From a review of their experimental details, it looks as if they were generating recombinant DNA of the viruses using WIV1 as the backbone but I could not determine if they were using Seemless Cloning techniques. I could not determine exactly where they were conducting these gain of function experiments. I know UNC-Chapel Hill has done these but within the document, I could not determine where this was occurring. Do you know where this was occurring? It then appears that the recombinant DNA of the virus was then injected into humanized mice. However, again I couldn't determine where this occurred or was to occur. On page 187 of the same SF 424 under "Vertebrate Animals" it indicates that work with vertebrate animals will be conducted at Wuhan University at the School of Medicine and UNC - CH. Then under "Laboratory Mice" it states that lab mice will be sourced commercially by Wuhan Center for Animal Experiment at ing ot (Db >E2 Expressing Mice with on experiments as described this occurred? Wuhan University and that humanized mice will be bread at University of Wuhan and UNC - CH. Furthermore, the mice will be inoculated with the virus. Under "UNC Facilities where selected agents to be used" it continues with all mouse studies at UNC-CH will be performed...." However, on page 200 of the same SF 424 there is a letter from UNC - CH stating "The work to be performed by UNC-CH does not include animal and/or human research subjects." I know that was a lot of information but where exactly was the experimentation of injecting the humanized mice with the recombinant DNA occurring? SF 424 AI110964-01 (received date 06/05/2013) In this SF 424 Aim 3 seems indicative of gain of function experimentation (C3a and C3b) although it does not use that exact term. On page 119 of AI110964-01 under "C3d) Humanized mouse in vivo infection experiments" it states that humanized mouse in vivo experiments in humanized mice was occurring at the Wuhan Institute of Virology. I did not see the location where these gain of function experiments were being done but if the injections were occurring at WIV then was the recombinant DNA also generated at WIV? Was Seemless Cloning also being done? RPPR (AI110964-05) Finally, in the RPPR (6/1/2017-5/31/2018) on page 28 under "In Vivo Infection of Human ACE2 Expressing Mice with SARSr-Cov S Protein variants", it appears to be showing the results from their gain of function experiments as described in the SF 424. This is more of less the same as the question above, but do you know where this occurred? LiF
-
Good afternoon Emily, OMA/DPI received questions related to an FBI inquiry for the following NIAID grants: 1R01AI110964-01 through 2R01AI110964-06. The agent is requesting clarification on the details of the study, where certain aspects were performed, and whether seamless cloning techniques were used. I note you were the last official to sign off on 4/27/20. Would you be able to provide a response to the below-captured questions and/or be available for a joint call with our office and the agent? If not, who would be the best SME on this matter? I'm sure you understand, since this is a sensitive matter, we need to maintain confidentiality and limit the touch-points within NIH. I'm happy to discuss further if you have any questions. Thank you, Ashley Ashley M. Sanders, MPS Senior Program Investigations Officer NIH, OMA, Division Program Integrity 6011 Executive Blvd. Rockville, Maryland 20852 Office: @nih.gov FBI Questions: vt tes en at ing ot (Db >E2 Expressing Mice with on experiments as described this occurred? SF 424 AI110964-06 (received date 11/05/2018) Both SF 424s seem to be describing "gain of function" experiments. On page 192 of SF 424 AI110964-06 (received date 11/05/2018) under P3CO Research, it indicates they are conducting gain of function of SARSr-CoV. Were they also conducting Seemless Cloining and Assembly? From a review of their experimental details, it looks as if they were generating recombinant DNA of the viruses using WIV1 as the backbone but I could not determine if they were using Seemless Cloning techniques. I could not determine exactly where they were conducting these gain of function experiments. I know UNC-Chapel Hill has done these but within the document, I could not determine where this was occurring. Do you know where this was occurring? It then appears that the recombinant DNA of the virus was then injected into humanized mice. However, again I couldn't determine where this occurred or was to occur. On page 187 of the same SF 424 under "Vertebrate Animals" it indicates that work with vertebrate animals will be conducted at Wuhan University at the School of Medicine and UNC - CH. Then under "Laboratory Mice" it states that lab mice will be sourced commercially by Wuhan Center for Animal Experiment at Wuhan University and that humanized mice will be bread at University of Wuhan and UNC - CH. Furthermore, the mice will be inoculated with the virus. Under "UNC Facilities where selected agents to be used" it continues with all mouse studies at UNC-CH will be performed...." However, on page 200 of the same SF 424 there is a letter from UNC - CH stating "The work to be performed by UNC-CH does not include animal and/or human research subjects." I know that was a lot of information but where exactly was the experimentation of injecting the humanized mice with the recombinant DNA occurring? SF 424 AI110964-01 (received date 06/05/2013) In this SF 424 Aim 3 seems indicative of gain of function experimentation (C3a and C3b) although it does not use that exact term. On page 119 of AI110964-01 under "C3d) Humanized mouse in vivo infection experiments" it states that humanized mouse in vivo experiments in humanized mice was occurring at the Wuhan Institute of Virology. I did not see the location where these gain of function experiments were being done but if the injections were occurring at WIV then was the recombinant DNA also generated at WIV? Was Seemless Cloning also being done? RPPR (AI110964-05) Finally, in the RPPR (6/1/2017-5/31/2018) on page 28 under "In Vivo Infection of Human ACE2 Expressing Mice with SARSr-Cov S Protein variants", it appears to be showing the results from their gain of function experiments as described in the SF 424. This is more of less the same as the question above, but do you know where this occurred? SF 424 AI110964-06 (received date 11/05/2018) Both SF 424s seem to be describing "gain of function" experiments. On page 192 of SF 424 AI110964-06 (received date 11/05/2018) under P3CO Research, it indicates they are conducting gain of function of SARSr-CoV. The funding pause on gain-of-function (GoF) experiments was in place from 2014-2017, and explicitly involved work reasonably anticipated to enhance the transmissibility or pathogenicity of influenza, MERS-CoV, or SARS-CoV. As such, that policy would not have applied to SARS-related coronaviruses (SARSr-CoV). The replacement policy, Potential Pandemic Pathogen Care and Oversight (P3CO), requires additional review and oversight of experiments that are anticipated to increase a potential pandemic pathogen's transmissibility or pathogenicity in humans. The viruses created under this award are chimeric bat viruses, which generally would not be anticipated to cause enhanced disease or transmission in people. When evaluating experiments for potential GoF or P3CO we determine the likelihood of altering one of these attributes compared to the wild-type or circulating viral strain. Were they also conducting Seemless Cloining and Assembly? From a review of their experimental details, it looks as if they were generating recombinant DNA of the viruses using WIV1 as the backbone but I could not determine if they were using Seemless Cloning techniques. I'm not aware of them using seamless cloning. Standard techniques for investigators in this field are to create cDNA molecular clones, which are then expressed in cull culture. I could not determine exactly where they were conducting these gain of function experiments. I know UNC-Chapel Hill has done these but within the document, I could not determine where this was occurring. Do you know where this was occurring? GoF experiments were not conducted as part of this award. While chimeric viruses were created via this award, they would not be considered GoF since the results did not confer attributes that were not already exhibited by the wild type versions of the viruses. For example, expressing the spike protein of SARS-CoV in the WIV-1 backbone did not increase the pathogenicity of WIV-1 beyond that of SARS-CoV. This award did not support work to manipulate CoV genomes or create chimeric viruses at Wuhan Institute of Virology; such work was performed at UNC-CH. It then appears that the recombinant DNA of the virus was then injected into humanized mice. However, again I couldn't determine where this occurred or was to occur. On page 187 of the same SF 424 under "Vertebrate Animals" it indicates that work with vertebrate animals will be conducted at Wuhan University at the School of Medicine and UNC - CH. Then under "Laboratory Mice" it states that lab mice will be sourced commercially by Wuhan Center for Animal Experiment at Wuhan University and that humanized mice will be bread at University of Wuhan and UNC - CH. Furthermore, the mice will be inoculated with the virus. Recombinant viral cDNA is not directly injected into humanized mice. Rather, these molecular clones are used to grow virus in culture to create an inoculum used in infectivity studies. Both WIV and UNCCH performed studies with molecular clones, which included infecting mice with the resulting recombinant viruses. Under "UNC Facilities where selected agents to be used" it continues with all mouse studies at UNC-CH will be performed...." However, on page 200 of the same SF 424 there is a letter from UNC - CH stating C3b "The work to be performed by UNC-CH does not include animal and/or human research subjects." I know that was a lot of information but where exactly was the experimentation of injecting the humanized mice with the recombinant DNA occurring? I believe this to be a typographical error on the part of UNC's business office. The application describes animal work at UNC. Budget justifications and the consortium agreement also include references to this work. I believe UNC mean to say that the work "... does not include human research subjects." SF 424 AI110964-01 (received date 06/05/2013) In this SF 424 Aim 3 seems indicative of gain of function experimentation (C3a and C3b) although it does not use that exact term. The receipt date of this application was June of 2013, and the term "gain-of-function" was not widely used before the USG funding pause was announced in 2014. C3a and C3b describe work using pseudovirus assays, which would not have been considered GoF as they do not involve creating full replicating viruses. On page 119 of AI110964-01 under "C3d) Humanized mouse in vivo infection experiments" it states
-
2020-05-13 11:59
Ashley Sanders
Good afternoon Emily, OMA/DPI received questions related to an FBI inquiry for the following NIAID grants: 1R01AI110964-01 through 2R01AI110964-06. The agent is requesting clarification on the details of the study, where certain aspects were performed, and whether seamless cloning techniques were used. I note you were the last official to sign off on 4/27/20. Would you be able to provide a response to the below-captured questions and/or be available for a joint call with our office and the agent? If not, who would be the best SME on this matter? I'm sure you understand, since this is a sensitive matter, we need to maintain confidentiality and limit the touch-points within NIH. I'm happy to discuss further if you have any questions. Thank you, Ashley y't tes ing rt (Db >E2 Expressing Mice with dn experiments as described this occurred? Ashley M. Sanders, MPS Senior Program Investigations Officer NIH, OMA, Division Program Integrity 6011 Executive Blvd. Rockville, Maryland 20852 Office: @nih.gov FBI Questions: SF 424 AI110964-06 (received date 11/05/2018) Both SF 424s seem to be describing "gain of function" experiments. On page 192 of SF 424 AI110964-06 (received date 11/05/2018) under P3CO Research, it indicates they are conducting gain of function of SARSr-CoV. Were they also conducting Seemless Cloining and Assembly? From a review of their experimental details, it looks as if they were generating recombinant DNA of the viruses using WIV1 as the backbone but I could not determine if they were using Seemless Cloning techniques. I could not determine exactly where they were conducting these gain of function experiments. I know UNC-Chapel Hill has done these but within the document, I could not determine where this was occurring. Do you know where this was occurring? It then appears that the recombinant DNA of the virus was then injected into humanized mice. However, again I couldn't determine where this occurred or was to occur. On page 187 of the same SF 424 under "Vertebrate Animals" it indicates that work with vertebrate animals will be conducted at Wuhan University at the School of Medicine and UNC - CH. Then under "Laboratory Mice" it states that lab mice will be sourced commercially by Wuhan Center for Animal Experiment at Wuhan University and that humanized mice will be bread at University of Wuhan and UNC - CH. Furthermore, the mice will be inoculated with the virus. Under "UNC Facilities where selected agents to be used" it continues with all mouse studies at UNC-CH will be performed...." However, on page 200 of the same SF 424 there is a letter from UNC - CH stating "The work to be performed by UNC-CH does not include animal and/or human research subjects." I know that was a lot of information but where exactly was the experimentation of injecting the humanized mice with the recombinant DNA occurring? SF 424 AI110964-01 (received date 06/05/2013) In this SF 424 Aim 3 seems indicative of gain of function experimentation (C3a and C3b) although it does not use that exact term. On page 119 of AI110964-01 under "C3d) Humanized mouse in vivo infection experiments" it states that humanized mouse in vivo experiments in humanized mice was occurring at the Wuhan Institute of Virology. I did not see the location where these gain of function experiments were being done but if the injections were occurring at WIV then was the recombinant DNA also generated at WIV? Was Seemless Cloning also being done? RPPR (AI110964-05) Finally, in the RPPR (6/1/2017-5/31/2018) on page 28 under "In Vivo Infection of Human ACE2 Expressing Mice with SARSr-Cov S Protein variants", it appears to be showing the results from their gain of function experiments as described in the SF 424. This is more of less the same as the question above, but do you know where this occurred? We might also want to include OGC / Anna Jacobs in our .0964-06 1d just sent the following response to 0 AM
-
2rtain aspects were fficial to sign off on 4/27/20. you understand, since this is a sensitive I'm happy to discuss further if you have rt tes en at ing rt (Db ACE2 Expressing Mice with ction experiments as described Good afternoon Emily, OMA/DPI received questions related to an FBI inquiry for the following NIAID grants: 1R01AI110964-01 through 2R01AI110964-06. The agent is requesting clarification on the details of the study, where certain aspects were performed, and whether seamless cloning techniques were used. I note you were the last official to sign off on 4/27/20. Would you be able to provide a response to the below-captured questions and/or be available for a joint call with our office and the agent? If not, who would be the best SME on this matter? I'm sure you understand, since this is a sensitive matter, we need to maintain confidentiality and limit the touch-points within NIH. I'm happy to discuss further if you have any questions. Thank you, Ashley Ashley M. Sanders, MPS Senior Program Investigations Officer NIH, OMA, Division Program Integrity 6011 Executive Blvd. Rockville, Maryland 20852 Office: @nih.gov FBI Questions: SF 424 AI110964-06 (received date 11/05/2018) Both SF 424s seem to be describing "gain of function" experiments. On page 192 of SF 424 AI110964-06 (received date 11/05/2018) under P3CO Research, it indicates they are conducting gain of function of SARSr-CoV. Were they also conducting Seemless Cloining and Assembly? From a review of their experimental details, it looks as if they were generating recombinant DNA of the viruses using WIV1 as the backbone but I could not determine if they were using Seemless Cloning techniques. I could not determine exactly where they were conducting these gain of function experiments. I know UNC-Chapel Hill has done these but within the document, I could not determine where this was occurring. Do you know where this was occurring? It then appears that the recombinant DNA of the virus was then injected into humanized mice. However, again I couldn't determine where this occurred or was to occur. On page 187 of the same SF 424 under "Vertebrate Animals" it indicates that work with vertebrate animals will be conducted at Wuhan University at the School of Medicine and UNC - CH. Then under "Laboratory Mice" it states that lab mice will be sourced commercially by Wuhan Center for Animal Experiment at Wuhan University and that humanized mice will be bread at University of Wuhan and UNC - CH. Furthermore, the mice will be inoculated with the virus. Under "UNC Facilities where selected agents to be used" it continues with all mouse studies at UNC-CH will be performed...." However, on page 200 of the same SF 424 there is a letter from UNC - CH stating "The work to be performed by UNC-CH does not include animal and/or human research subjects." I know that was a lot of information but where exactly was the experimentation of injecting the humanized mice with the recombinant DNA occurring? SF 424 AI110964-01 (received date 06/05/2013) In this SF 424 Aim 3 seems indicative of gain of function experimentation (C3a and C3b) although it does not use that exact term. On page 119 of AI110964-01 under "C3d) Humanized mouse in vivo infection experiments" it states that humanized mouse in vivo experiments in humanized mice was occurring at the Wuhan Institute of Virology. I did not see the location where these gain of function experiments were being done but if the injections were occurring at WIV then was the recombinant DNA also generated at WIV? Was Seemless Cloning also being done? RPPR (AI110964-05) Finally, in the RPPR (6/1/2017-5/31/2018) on page 28 under "In Vivo Infection of Human ACE2 Expressing Mice with SARSr-Cov S Protein variants", it appears to be showing the results from their gain of function experiments as described this occurred? in the SF 424. This is more of less the same as the question above, but do you know where this occurred? I could ask Melanie to « this Sunday; I'd be .0964-06
-
Good afternoon Emily, OMA/DPI received questions related to an FBI inquiry for the following NIAID grants: 1R01AI110964-01 through 2R01AI110964-06. The agent is requesting clarification on the details of the study, where certain aspects were performed, and whether seamless cloning techniques were used. I note you were the last official to sign off on 4/27/20. Would you be able to provide a response to the below-captured questions and/or be available for a joint call with our office and the agent? If not, who would be the best SME on this matter? I'm sure you understand, since this is a sensitive matter, we need to maintain confidentiality and limit the touch-points within NIH. I'm happy to discuss further if you have any questions. Thank you, Ashley Ashley M. Sanders, MPS Senior Program Investigations Officer NIH, OMA, Division Program Integrity 6011 Executive Blvd. y't tes ing rt (Db -E2 Expressing Mice with dn experiments as described this occurred? Rockville, Maryland 20852 Office: @nih.gov FBI Questions: SF 424 AI110964-06 (received date 11/05/2018) Both SF 424s seem to be describing "gain of function" experiments. On page 192 of SF 424 AI110964-06 (received date 11/05/2018) under P3CO Research, it indicates they are conducting gain of function of SARSr-CoV. Were they also conducting Seemless Cloining and Assembly? From a review of their experimental details, it looks as if they were generating recombinant DNA of the viruses using WIV1 as the backbone but I could not determine if they were using Seemless Cloning techniques. I could not determine exactly where they were conducting these gain of function experiments. I know UNC-Chapel Hill has done these but within the document, I could not determine where this was occurring. Do you know where this was occurring? It then appears that the recombinant DNA of the virus was then injected into humanized mice. However, again I couldn't determine where this occurred or was to occur. On page 187 of the same SF 424 under "Vertebrate Animals" it indicates that work with vertebrate animals will be conducted at Wuhan University at the School of Medicine and UNC - CH. Then under "Laboratory Mice" it states that lab mice will be sourced commercially by Wuhan Center for Animal Experiment at Wuhan University and that humanized mice will be bread at University of Wuhan and UNC - CH. Furthermore, the mice will be inoculated with the virus. Under "UNC Facilities where selected agents to be used" it continues with all mouse studies at UNC-CH will be performed...." However, on page 200 of the same SF 424 there is a letter from UNC - CH stating "The work to be performed by UNC-CH does not include animal and/or human research subjects." I know that was a lot of information but where exactly was the experimentation of injecting the humanized mice with the recombinant DNA occurring? SF 424 AI110964-01 (received date 06/05/2013) In this SF 424 Aim 3 seems indicative of gain of function experimentation (C3a and C3b) although it does not use that exact term. On page 119 of AI110964-01 under "C3d) Humanized mouse in vivo infection experiments" it states that humanized mouse in vivo experiments in humanized mice was occurring at the Wuhan Institute of Virology. I did not see the location where these gain of function experiments were being done but if the injections were occurring at WIV then was the recombinant DNA also generated at WIV? Was Seemless Cloning also being done? RPPR (AI110964-05) Finally, in the RPPR (6/1/2017-5/31/2018) on page 28 under "In Vivo Infection of Human ACE2 Expressing Mice with SARSr-Cov S Protein variants", it appears to be showing the results from their gain of function experiments as described in the SF 424. This is more of less the same as the question above, but do you know where this occurred? 0) (e)" > .0964-06 ed t's going on in this space
-
Good afternoon Emily, OMA/DPI received questions related to an FBI inquiry for the following NIAID grants: 1R01AI110964-01 through 2R01AI110964-06. The agent is requesting clarification on the details of the study, where certain aspects were performed, and whether seamless cloning techniques were used. I note you were the last official to sign off on 4/27/20. Would you be able to provide a response to the below-captured questions and/or be available for a joint call with our office and the agent? If not, who would be the best SME on this matter? I'm sure you understand, since this is a sensitive matter, we need to maintain confidentiality and limit the touch-points within NIH. I'm happy to discuss further if you have any questions. yt tes ing rt (Db >E2 Expressing Mice with dn experiments as described this occurred? Thank you, Ashley Ashley M. Sanders, MPS Senior Program Investigations Officer NIH, OMA, Division Program Integrity 6011 Executive Blvd. Rockville, Maryland 20852 Office: @nih.gov FBI Questions: SF 424 AI110964-06 (received date 11/05/2018) Both SF 424s seem to be describing "gain of function" experiments. On page 192 of SF 424 AI110964-06 (received date 11/05/2018) under P3CO Research, it indicates they are conducting gain of function of SARSr-CoV. Were they also conducting Seemless Cloining and Assembly? From a review of their experimental details, it looks as if they were generating recombinant DNA of the viruses using WIV1 as the backbone but I could not determine if they were using Seemless Cloning techniques. I could not determine exactly where they were conducting these gain of function experiments. I know UNC-Chapel Hill has done these but within the document, I could not determine where this was occurring. Do you know where this was occurring? It then appears that the recombinant DNA of the virus was then injected into humanized mice. However, again I couldn't determine where this occurred or was to occur. On page 187 of the same SF 424 under "Vertebrate Animals" it indicates that work with vertebrate animals will be conducted at Wuhan University at the School of Medicine and UNC - CH. Then under "Laboratory Mice" it states that lab mice will be sourced commercially by Wuhan Center for Animal Experiment at Wuhan University and that humanized mice will be bread at University of Wuhan and UNC - CH. Furthermore, the mice will be inoculated with the virus. Under "UNC Facilities where selected agents to be used" it continues with all mouse studies at UNC-CH will be performed...." However, on page 200 of the same SF 424 there is a letter from UNC - CH stating "The work to be performed by UNC-CH does not include animal and/or human research subjects." I know that was a lot of information but where exactly was the experimentation of injecting the humanized mice with the recombinant DNA occurring? SF 424 AI110964-01 (received date 06/05/2013) In this SF 424 Aim 3 seems indicative of gain of function experimentation (C3a and C3b) although it does not use that exact term. On page 119 of AI110964-01 under "C3d) Humanized mouse in vivo infection experiments" it states that humanized mouse in vivo experiments in humanized mice was occurring at the Wuhan Institute of Virology. I did not see the location where these gain of function experiments were being done but if the injections were occurring at WIV then was the recombinant DNA also generated at WIV? Was Seemless Cloning also being done? RPPR (AI110964-05) Finally, in the RPPR (6/1/2017-5/31/2018) on page 28 under "In Vivo Infection of Human ACE2 Expressing Mice with SARSr-Cov S Protein variants", it appears to be showing the results from their gain of function experiments as described in the SF 424. This is more of less the same as the question above, but do you know where this occurred? wh.iov.cn> 20 6:30 AM EDT
-
Good afternoon, We are following up on a time-sensitive request for information from the FBI. Please let us know if you are able to accommodate their request or if you can recommend a POC to address the concerns. Thank you, Ashley